Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers

Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to induction of cytochrome P450 3A by rifampin. In th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: la Porte, C. J. L., Colbers, E. P. H., Bertz, R., Voncken, D. S., Wikstrom, K., Boeree, M. J., Koopmans, P. P., Hekster, Y. A., Burger, D. M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2004
Materias:
Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC400571/
https://ncbi.nlm.nih.gov/pubmed/15105105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.5.1553-1560.2004
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares